lung cancer

[British Journal of Cancer] Researchers reported a novel blood-based biomarker panel for early diagnosis, monitoring of therapeutic response, and prognostic evaluation of patients with NSCLC brain metastasis.

[Future Oncology] The authors take stock of the relationship between epidermal growth factor receptor (EGFR) mutations and PD-1 and its ligand receptor 1expression and summarize the important clinical studies on immunotherapy-inhibitor-based treatment in patients with EGFR-TKI-resistant NSCLC.

[Molecular Cancer] Scientists appraise current literature, opportunities, and challenges associated with liquid biopsy and pharmacogenomic testing as precision therapy tools in the management of epidermal growth factor receptor (EGFR) mutant and resistant lung cancers.

[Toxicological Sciences] Researchers investigated the mechanism of hexavalent chromium carcinogenesis focusing on the role of the epitranscriptomic dysregulation.

[Akeso, Inc. (BioSpace, Inc.)] -Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer.

[Bristol Myers Squibb] Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Application for Opdivo plus chemotherapy for the neoadjuvant treatment of patients with resectable non-small cell lung cancer.